BRYNJELSEN SEAN 4

What Happened
Sean Brynjelsen, President, CEO and a director of Eton Pharmaceuticals (ETON), sold a total of 120,000 shares in open-market transactions on May 28, 2026. The filing reports two sale entries: 119,852 shares at a weighted average price of $31.88 (proceeds $3,820,882) and 148 shares at $32.67 (proceeds $4,835). Combined proceeds were approximately $3,825,717. These were sales (not purchases) and generally represent liquidity rather than a bullish insider buy.

Key Details

• Transaction date: May 28, 2026 (reported on Form 4 filed May 29, 2026) — filing appears timely.
• Reported prices: primary lot weighted average $31.88 (119,852 shares); a second small lot at $32.67 (148 shares).
• Total shares sold: 120,000; total reported proceeds ≈ $3,825,717.
• Footnotes: F1 notes the larger block was sold in multiple trades at prices ranging $31.59–$32.55 (the $31.88 is a weighted average). F2 states the reporting person will provide full per-trade price details upon request.
• Shares owned after transaction: not provided here — check the filed Form 4 for post-sale holdings.

Context
This filing documents open-market sales by the company's CEO. Sales by executives can be for many routine reasons (diversification, tax planning, liquidity) and are not by themselves a clear signal about company prospects. No options exercises, awards, or gifts are reported in these transactions.